cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Prasetyadi Mawardi
Contact Email
prasetyadimawardi@yahoo.com
Phone
+6287834999959
Journal Mail Official
jurnalibehs@gmail.com
Editorial Address
Bagian Pendidikan & Penelitian RSUD Dr. Moewardi Jl. Kol. Soetarto 132 Fax (0271) 666954 Surakarta
Location
Kota surakarta,
Jawa tengah
INDONESIA
Indonesian Basic and Experimental Health Sciences
Published by RSUD Dr. Moewardi
ISSN : -     EISSN : 30255929     DOI : 10.11594/ibehs
Core Subject : Health,
Health Professions Medicine & Pharmacology Nursing Public Health
Indonesian Basic and Experimental Health Sciences Journal (IBEHS) is a health journal published by RSUD Dr. Moewardi Surakarta, Central Java, Indonesia as a contribution to RSUD Dr. Moewardi for the development and progress of health science which is marked by various innovations and creativity of health workers, both in the Dr. Moewardi or other health workers who are always concerned about education, research, and community service in the health sector.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 25 Documents
 1   2   3 
The Differences In The Quality Of Mixed Material Radiation Aprons At Dr. Moewardi Hospital With A Review Of Attenuation Coefficient Analysis Alviana Hapsari Purbarani; Umaimah, Umi; Eka Prasetya, Firman
Indonesian Basic and Experimental Health Sciences Vol. 14 No. 1 (2025): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol14iss1pp73-79

Abstract

IntroductionRadiation aprons are essential protective equipment in radiology, and the Regulation of the Head of BAPETEN No. 4 of 2020 requires aprons in Diagnostic and Interventional Radiology units to provide protection equivalent to 0.25 mmPb, 0.35 mmPb, or 0.5 mmPb. This study aimed to evaluate the quality of mixed-material radiation aprons at Dr. Moewardi Hospital by analyzing their attenuation coefficients. MethodsThis study assessed several apron brands available in the Radiology Installation and Cathlab Unit. Measurements were performed using a GE Proteus X-ray machine and a Raysafe X-ray Multimeter Detector. The X-ray parameters were set at 100 kV, 10 mAs, 100 cm tube-to-detector distance, and a 5 × 5 cm irradiation field, with variations in apron thickness. The reference attenuation coefficient of Pb under the same parameters was calculated as 6.32 mm⁻¹. Apron brands tested included Primax 0.35 mmPb, ProteX 0.5 mmPb, Infab 0.25 mmPb, Lead X 0.25 mmPb, Rayshield 0.25 mmPb, Xenolite 0.35 mmPb, and Trucomfii 0.5 mmPb. Results The attenuation coefficients obtained were 4.67 mm⁻¹, 4.49 mm⁻¹, 4.476 mm⁻¹, 3.94 mm⁻¹, 3.04 mm⁻¹, 2.63 mm⁻¹, and 2.22 mm⁻¹, respectively. The highest coefficient was observed in the Lead X 0.25 mmPb apron. All apron attenuation coefficients were lower than the Pb reference value. ConclusionAll mixed-material aprons evaluated demonstrated lower attenuation coefficients compared with pure Pb under identical exposure conditions. These findings indicate variability in protective performance across brands, highlighting the need for routine quality assessment to ensure compliance with regulatory requirements.
The Differences In The Occurrence Of Drug-Related Problems And The Duration Of The Assessment Of Pediatric Chemotherapy Prescriptions Before And After The Implementation Of The Electronic-Based Cytotoxic Drug Reconstitution Guidance System At Dr. Moewardi Hospital: Pharmaceutical Installation of Dr. Moewardi Hospital Pridiyanto; Agus Suryadi, Bambang; Shaffira, Mutthia; Zaroh, Fatimah
Indonesian Basic and Experimental Health Sciences Vol. 14 No. 1 (2025): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol14iss1pp65-72

Abstract

Abstract. Introduction Assessment of pediatric chemotherapy prescriptions is essential for preventing Drug-Related Problems (DRPs). A preliminary review showed that 57% of pediatric injectable chemotherapy patients were at risk of potential DRPs, contributing to prolonged assessment times. These issues indicate the need for systematic improvements to enhance medication safety and workflow efficiency. This study aimed to evaluate differences in DRP incidence and prescription assessment duration before and after implementing an electronic cytotoxic reconstitution guidance system. Method An experimental design was used to compare assessments before and after implementation of the electronic guidance system. A total of 60 pediatric chemotherapy prescriptions were analyzed, consisting of 30 assessed without the system (control) and 30 assessed after implementation (treatment). DRP occurrences were documented, and assessment duration was measured in minutes and seconds. Statistical analyses were performed to identify differences between groups, with significance set at P < 0.05. Results In the control group, 26 DRPs were identified, compared with 6 in the treatment group. Statistical analysis confirmed that the guidance system significantly reduced DRP incidence (P < 0.05). The mean assessment duration also decreased substantially from 7 minutes 2 seconds before implementation to 3 minutes 18 seconds afterward, and this reduction was statistically significant (P < 0.05). Conclussion The electronic cytotoxic reconstitution guidance system effectively enhances the safety and efficiency of pediatric chemotherapy prescription assessments. It significantly reduces DRP incidence and shortens assessment duration, demonstrating its value in improving workflow and supporting safer chemotherapy services.
Low Serum Anti Mullerian Hormone as a Risk Factor for Cardiovascular Disease in Child-Bearing Age Women Ratnani, Daniela; Pramudianti, M.I. Diah
Indonesian Basic and Experimental Health Sciences Vol. 14 No. 1 (2025): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol14iss1pp80-88

Abstract

IntroductionCardiovascular disease (CVD) is the leading cause of global death. Incidence of having CVD is influenced by general risk factors and gender-related risk (preeclampsia, miscarriage, premature birth, contraception and hormonal therapy). Women of childbearing age have lower risk of CVD than men. Anti Mullerian Hormone (AMH) can be used to predict CVD. This study aimed to know association between Serum AMH level with CVD. MethodsThis study was an observational analytic, cross-sectional study. Subjects study is women with childbearing age (18-44 years old) who doing laboratory examination from May until November 2024. The exclusion criteria were patients who under chemoradiation therapy, pregnancy and have history of fertility disorder such as polycystic ovarian syndrome (PCOS). Data was subjected to bivariate testung chi square and multivariate regression logistic with Statistical Package for the Sociak Sciences (SPSS) version 29.0. ResultsA total of 57 subjects were being analyzed. Bivariate analysis showed that Serum AMH (p<0,001) have correlation with CVD. Multivariate analysis shows that Serum AMH <0,69 ng/mL (p<0,001; RR=34,049) were independently associated with CVD. ConclusionsSerum AMH <0,69 ng/mL (PR:34,05; 95% CI: 6,245–185,630, p=<0,001) increased risk of having CVD in women with childbearing age.
Can the Calculator Clinic Deter Hypoglycemia, Prevent Hypoglycemia in Hemodialysis Patients, and Reduce D40% Use? Anindhita, Rakhma; Kiswanto, Agus; Noviana, Siska Andika; Juwandi, Juwandi; Darmawan, Rendi Editya
Indonesian Basic and Experimental Health Sciences Vol. 14 No. 1 (2025): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol14iss1pp89-97

Abstract

IntroductionHypoglycemia is a common complication in diabetic nephropathy (DN) patients undergoing hemodialysis. Early detection is essential to prevent adverse outcomes. A calculator-based clinical tool (cyclic hypoglycemia calculator) was developed to estimate hypoglycemia risk and guide additional glucose needs. This study aimed to analyze the effect of using the calculator on preventing hypoglycemia during hemodialysis. MethodsA quasi-experimental pre–post test control group design was conducted among hemodialysis patients at Dr. Moewardi Hospital (March–July 2024). Samples were selected via simple random sampling: odd medical record numbers for the control group and even numbers for the intervention group. The intervention group received hypoglycemia-risk calculation and glucose adjustment recommendations, while the control group followed standard procedures. Blood glucose levels were measured before and after 4-hour hemodialysis using a standardized glucometer. Data were homogeneous (P=0.903) and non-normally distributed (P=0.00), so the Mann–Whitney test was applied. ResultsThere was no significant difference in blood glucose levels between groups (P=0.811). Pre-dialysis glucose levels were similar (115.45 vs. 114.71 mg/dL), and post-dialysis levels remained comparable (99.39 vs. 98.21 mg/dL). In the control group, 33% experienced increased glucose, 3% remained unchanged, and 64% decreased, with an average reduction of 33.67 mg/dL. In the intervention group, 36% increased and 64% decreased, with an average reduction of 24.5 mg/dL. ConclusionsThe hypoglycemia-deterrent calculator did not produce significant differences in glucose levels compared with standard care. However, its use showed 75% efficiency in reducing unnecessary D40% administration. Further studies are recommended to refine D40% dosing strategies during hemodialysis based on individualized risk scoring.
Combined Immunosuppressive Therapy (Corticosteroid-Cyclosporine) on Hospital Stay in Patients with SevereCutaneous Adverse Reactions perspective of health worker: A Qualitative Study Widhiati, Suci; -, Hastika Dwi Oktiningrum; Tansil, Ivana; Arrosyid, Azhar
Indonesian Basic and Experimental Health Sciences Vol. 14 No. 1 (2025): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol14iss1pp98-102

Abstract

IntroductionSevere cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS are rare but life-threatening conditions requiring intensive inpatient care. Corticosteroids remain the main therapy but may prolong hospitalization and increase complications. Combining corticosteroids with cyclosporine has been considered to improve patient outcomes. This study explored healthcare professionals’ perspectives on the impact of this therapy combination on hospitalization duration for SCAR patients. MethodsA qualitative exploratory study was conducted at Dr. Moewardi General Hospital, Surakarta (August–October 2023). Purposive sampling recruited 12 healthcare professionals (3 consultants, 5 residents, 4 nurses) involved in SCAR management. Semi-structured interviews explored diagnostic confidence, treatment approaches, and hospitalization duration. Data were analyzed using thematic analysis. ResultPhysicians reported high diagnostic confidence, with typical hospital stays ranging from 14–30 days. Most favored corticosteroid–cyclosporine combination therapy, perceiving faster recovery and fewer complications. Barriers included limited drug availability, unfamiliarity with dosing, and safety concerns. Nurses emphasized wound care challenges, infection risks, and psychosocial needs. Both groups underlined the importance of multidisciplinary collaboration and family involvement in optimizing patient outcomes. ConclusionHealthcare professionals perceive corticosteroid–cyclosporine combination therapy as potentially effective in shortening hospitalization and reducing complications among SCAR patients. Institutional support, clinician training, and further clinical research are recommended to strengthen its implementation.

Page 3 of 3 | Total Record : 25

 1   2   3 

Filter by Year

2023 2025


Reset
Filter By Issues
All Issue Vol. 14 No. 1 (2025): November Vol. 13 No. 2 (2025): APRIL Vol. 13 No. 1 (2024): November Vol. 12 No. 2 (2024): April Vol. 12 No. 1 (2023): November